COMET Trial Finds Active Monitoring Is a Viable Option for Some Patients With Low-risk DCIS - report from SABCS2024

Shelley Hwang, MD, MPH discusses active monitoring instead of upfront surgery may be a viable option for patients with hormone receptor-positive, HER2-negative, low-risk DCIS, according to results presented at San Antonio Breast Cancer Symposium 2024. Video: https://medicaldigest.org/scientific-contents/interview:comet-trial-finds-active-monitoring-viable-option-some-patients-low-risk-dcis